Haleon (NYSE:HLN – Get Rating) had its target price lifted by Barclays from GBX 360 ($4.45) to GBX 364 ($4.50) in a report issued on Tuesday morning, The Fly reports.
Separately, Morgan Stanley raised shares of Haleon from an equal weight rating to an overweight rating in a research report on Friday, January 6th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus target price of $364.00.
Haleon Price Performance
Shares of HLN opened at $8.08 on Tuesday. The stock has a 50 day simple moving average of $7.76. Haleon has a fifty-two week low of $5.59 and a fifty-two week high of $8.50.
Institutional Investors Weigh In On Haleon
Haleon Company Profile
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.
- Get a free copy of the StockNews.com research report on Haleon (HLN)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.